In striving to develop novel, targeted anticancer treatment strategies, research has recently focused on the development of agents that inhibit tumor angiogenesis (i.e. inhibit the creation of new blood vessels to the tumor from preexisting vessels).
This chapter describes advances in the design and development of agents for non-HIV infections.
Analysis of glutamyl-aminopeptidase inhibition has allowed the development of agents that effectively reduce blood pressure.
The development of agents or surface coatings with antimicrobial activity has gained increasing interest in recent years.
Our data should be helpful for designing the study in the development of agents acting on telomere and/or telomerase.
The development of agents capable of reducing or inhibiting the expression of MMPs could potentially lead to a slowing down or inhibition of articular cartilage destruction [2, 3].
Towards this, Beydoun et al. [5, 6, 7, 8] proposed development of agents in a way to decouple domain knowledge from problem solving knowledge.
A better understanding of the interplay among these substances will assist in the development of agents designed to ameliorate or reverse chronic pain.
Chemoprevention is a strategy that aims to reduce the incidence and burden of cancer through the development of agents to prevent, reverse or delay the carcinogenic process.
This chapter describes the general processes and concepts involved in the preclinical development of agents, with specific examples taken from the field of oncology.
The development of agents to prevent cancer requires an iterative process of target identification, preclinical testing, and early and late phase clinical trials to establish efficacy and safety.
